Ocular Therapeutix (OCUL) Misses Q1 EPS by 31c

Ocular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.49), $0.31 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $14.77 million versus the consensus estimate of $15.36 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright
• Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth